bausch.com - BLCO Profit before interest, taxes and amortization

Brandmark of bausch.com (BLCO)

Scalable lens production provides Bausch + Lomb Corporation (BLCO) with a steady cash flow, which impacts its debt load. Quarterly EBITDA captures this trend, where 912.18 represents the current metric. Capital optimization is being driven by the launch of innovative eye drops and INFUSE lenses, as well as the demand for vision correction and cataract treatment equipment.

Bausch + Lomb Corporation (BLCO) Profit before payment of interest, taxes and amortization: for the period 11/23/2025 - 11/16/2026

Bausch & Lomb (BLCO) - metric breakdowns and financial figures

- market value and analyst target forecast:
Fundamental company valuation:BLCO (bausch.com)
Manufactured products of Bausch + Lomb

Absolute operating profit reflects the cash flow from core operations before depreciation and taxes, measuring the real efficiency of the cash generator. By analyzing the EBITDA statistics of Bausch + Lomb Corporation (BLCO), an investor can see the impact of operating expenses on capital, which is critical for Bausch + Lomb Corporation (BLCO) due to the high cost of supporting a comprehensive ophthalmological ecosystem and the technological dependence of clinics on their equipment.

Competitors of Bausch + Lomb Corporation (BLCO)

Alcon Inc. (ALC) - Profit before interest, taxes and amortization|GKOS: Operating profit before deduction of amortization|Profit before interest, taxes and amortization Apellis|BLTE: Operating profit EBITDA|Profit before interest, taxes and amortization Ocular Pharma (OCUL)|Profit before payment of interest, taxes and amortization harrowinc.com|Viridian Therapeutics, Inc. (VRDN) - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization LENZ Therapeutics (LENZ)|Operating profit EBITDA Oculis AG (OCS)|eyepointpharma.com - Operating profit before deduction of amortization|KOD: Operating profit before amortization|Aldeyra Therapeutics Inc. - Operating profit EBITDA|KALA: Profit before payment of interest, taxes and amortization|IRD (Opus Bio) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization OKYO Pharma Limited (OKYO)|Profit before payment of interest, taxes and amortization adverum.com|Profit before interest, taxes and amortization Outlook Therapeutics Corp OTLK|Profit before payment of interest, taxes and amortization clearsidebio.com (CLSD)|NBY - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Kiora Pharmaceuticals Inc. KPRX|Operating profit EBITDA alimerasciences.com ALIM|Eyenovia, Inc. - Operating profit EBITDA|GHSI (Guardion Health Science) - Operating profit before amortization|OCUP (Ocuphire Pharma, Inc.) - Operating profit before deduction of amortization|Operating profit before deduction of amortization Opthea Limited